Rejected from The Lancet? The 7 Best Journals to Submit Next

The Lancet's editors screen submissions through two primary lenses:

Clinical significance at population scale. The Lancet wants findings that change how clinicians manage patients not just in one hospital system but globally. A well-designed RCT showing a 5% improvement in outcomes for a common condition will outperform a striking finding in a rare disease every time, because The Lancet measures impact in patient-years affected.

Global health relevance. This is where The Lancet differs most from its competitors. The journal has a decades-long commitment to global health equity, and editors actively prioritize research with implications for low- and middle-income countries. A surgical technique study from a single US academic center, even if methodologically perfect, is less attractive than a community health intervention study from sub-Saharan Africa.

Pattern 1: "Important finding, too specialized." The Lancet's editors thought your research was solid but belongs in a specialty journal. This is the most common desk rejection for clinical subspecialty papers. A cardiology trial, however large, competes for space against oncology, infectious disease, and public health papers. The Lancet can only publish about 300 original research papers per year.

Pattern 2: "Insufficient global relevance." Your study was rigorous but focused on a specific healthcare system, demographic, or geographic context without discussing broader implications. The Lancet editors want to know: does this matter in Mumbai as well as Munich?

Pattern 3: "Incremental advance." The Lancet prioritizes field-changing evidence. A confirmatory study, even a large one, may not meet their bar unless it resolves a genuine clinical controversy.

Pattern 4: "Study design concerns." Less common at the desk stage, but The Lancet has high standards for study design. Underpowered trials, observational studies where trials are feasible, and post-hoc analyses face an uphill battle.

The Lancet publishes a family of specialty journals, and editors routinely offer transfers:

• Lancet Oncology (IF ~42)
• Lancet Infectious Diseases (IF ~35)
• Lancet Neurology (IF ~44)
• Lancet Psychiatry (IF ~30)
• Lancet Respiratory Medicine (IF ~31)
• Lancet Digital Health (IF ~23)
• Lancet Global Health (IF ~34)
• Lancet Public Health (IF ~26)
• Lancet Diabetes and Endocrinology (IF ~30)
• Lancet Haematology (IF ~22)

These aren't consolation prizes. Several Lancet specialty journals have impact factors above 30, which puts them among the top journals in their respective fields. A paper in Lancet Oncology carries more weight in oncology than most papers in The Lancet itself.

If The Lancet offered a transfer, take it seriously. The receiving editor knows The Lancet's team found your work worthy of consideration, and your referee reports (if any) transfer with the manuscript.

Before choosing your next journal, a The Lancet manuscript fit check can tell you whether the issue was scope or something more fundamental to address first.

1. NEJM (New England Journal of Medicine)

NEJM is The Lancet's closest competitor and the journal most Lancet rejects should consider first. Both publish landmark clinical trials, but their editorial priorities diverge in instructive ways.

NEJM focuses heavily on clinical trial rigor and evidence that changes practice in the US and Europe. Where The Lancet asks "does this matter globally?", NEJM asks "does this change what doctors do tomorrow?" A large RCT with a clear clinical decision point that The Lancet rejected for being "too focused on Western healthcare systems" could be exactly what NEJM wants.

NEJM's review process is remarkably fast. Median time to first decision is about 21 days, which is faster than most specialty journals. The desk rejection rate is around 80%, similar to The Lancet's, so don't expect an easy ride.

Best for: Large clinical trials with practice-changing results. Drug and device trials. Papers where the clinical decision point is clear and immediate.

2. The BMJ

The BMJ shares The Lancet's commitment to global health and evidence-based medicine, but with a broader definition of what counts as impactful research. The BMJ publishes more epidemiology, health services research, and evidence synthesis than The Lancet, and it's generally more receptive to observational studies.

If The Lancet rejected your paper because it was observational rather than a trial, The BMJ is worth considering. The journal has been at the forefront of publishing and defending well-conducted observational research when trials aren't feasible.

The BMJ also has a strong open-peer-review tradition. Reviewers' names are disclosed to authors, which tends to produce more constructive feedback.

Best for: Epidemiology, health services research, evidence synthesis, and clinical research with policy implications. Papers with global health angles that The Lancet found too specialized.

3. JAMA

JAMA is the American counterpart to The Lancet and BMJ. If your study is primarily relevant to US clinical practice, JAMA is often a better fit than The Lancet, which prioritizes global applicability.

JAMA's editorial network includes several high-impact specialty journals (JAMA Oncology, JAMA Internal Medicine, JAMA Neurology, JAMA Cardiology, and others). If JAMA's editors think your paper belongs in a specialty journal, they may offer a transfer. JAMA Oncology (IF ~28) and JAMA Internal Medicine (IF ~39) are particularly strong.

Best for: Clinical research with clear relevance to US or North American medical practice. Well-designed trials in any clinical specialty. Studies on healthcare delivery, quality, and outcomes.

4. Lancet Oncology

If your paper is cancer-focused, Lancet Oncology is the strongest specialty alternative. With an IF around 42, it's the top cancer clinical journal alongside Journal of Clinical Oncology (JCO). Lancet Oncology publishes both clinical trials and translational research, though the emphasis is heavily clinical.

As a Lancet family journal, the editorial culture is familiar. If The Lancet desk-rejected your oncology paper for being "too specialized," Lancet Oncology is exactly where it belongs.

Best for: Clinical trials in oncology. Translational cancer research with clinical implications. Cancer epidemiology with policy relevance.

5. PLOS Medicine

PLOS Medicine occupies a unique position as a high-impact, open-access general medical journal. It's particularly receptive to research from low- and middle-income countries, systematic reviews, and health policy research, areas where The Lancet is also strong but where competition for space is fierce.

If The Lancet rejected your paper because of space constraints rather than quality concerns, PLOS Medicine can provide a similar audience without the bottleneck. The $4,600 APC is a consideration, but PLOS offers waivers for authors from qualifying countries.

Best for: Global health research, systematic reviews, health policy, and clinical research from resource-limited settings.

6. Annals of Internal Medicine

Annals of Internal Medicine is one of the top five general medical journals globally and is particularly strong for internal medicine, primary care, and health services research. It doesn't have The Lancet's global health emphasis but compensates with a deep commitment to clinical evidence that improves patient care.

Annals publishes the ACP (American College of Physicians) clinical guidelines, which gives it direct influence on practice. If your paper has guideline-changing potential in internal medicine, Annals is a strong fit.

Best for: Internal medicine research, systematic reviews that inform clinical practice, and health services research.

7. Nature Medicine

For papers at the translational interface, where basic science meets clinical application, Nature Medicine offers a home that neither The Lancet nor NEJM provides. Nature Medicine wants papers that reveal disease mechanisms with clinical implications, not just clinical outcomes.

If The Lancet rejected your paper because it was "too mechanistic" or "too translational," Nature Medicine is where that work is celebrated.

Best for: Translational research, disease mechanism studies with clinical relevance, and biomarker discovery papers.

Clinical trial rejected at the desk? Try NEJM first (if the trial is practice-changing) or a Lancet specialty journal (if the trial is in a specific disease area). Don't drop to a mid-tier journal unless NEJM and The BMJ both say no.

Public health/epidemiology paper rejected? The BMJ is the strongest alternative. PLOS Medicine is a solid open-access option. Lancet Global Health or Lancet Public Health may fit if the study has a clear geographic focus.

Rejected after peer review? Fix what reviewers flagged, then target NEJM, The BMJ, or JAMA. Include your existing peer review reports when submitting. Many top journals accept transferred reviews.

When moving from The Lancet to another journal, your cover letter needs to do specific work:

1. Explain the clinical significance in terms relevant to your new target journal's readership. NEJM readers care about practice change. The BMJ readers care about evidence and policy. JAMA readers care about outcomes that affect US clinical practice.

1. Don't mention The Lancet by name unless you're using the transfer system. No editor wants to feel like a backup choice.

1. Quantify the impact. "This trial enrolled 4,500 patients across 12 countries" is better than "this large international trial." Numbers establish credibility immediately.

1. Address global vs. local relevance honestly. If The Lancet rejected your paper for being too geographically focused, own that and explain why it matters to your new journal's specific audience.

Run your manuscript through a manuscript scope and readiness check to check it against journal-specific editorial criteria. It catches formatting issues, structural gaps, and scope mismatches before an editor does.

Resubmit to the same tier if:

• Reviewers praised the science but identified fixable issues
• You can address concerns within 2-3 months

Move to a different journal if:

• The rejection cited scope mismatch, not quality
• Your timeline needs a decision within 2-3 months

Reframe before resubmitting if:

• Reviewers found fundamental methodology concerns
• New experiments are needed to support the claims

In our pre-submission review work with manuscripts targeting The Lancet, four patterns generate the most consistent desk rejections worth knowing before resubmission.

Clinical significance insufficient for a global general medical readership. The Lancet's editorial standard requires that findings matter to clinicians and health policymakers across countries and healthcare systems, not just within the context of the study's setting. We see this failure as the most common pattern in Lancet desk rejections we review: rigorous clinical trials and cohort studies whose significance is clear within the high-income country context where the study was conducted but does not translate to diverse healthcare settings. In our review of Lancet submissions, we find that editors consistently require global health relevance to be demonstrated, not assumed.

Disease focus too narrow for a general medical audience. The Lancet publishes across all clinical medicine for a readership spanning all specialties. Papers addressing a question that is clearly important within one subspecialty but does not interest clinicians across medicine consistently fail the desk breadth test. We see this pattern in Lancet submissions we review present strong subspecialty findings where the cross-specialty relevance requires domain expertise to appreciate.

Incremental advance in a well-addressed clinical area. The Lancet wants practice-changing findings, not confirmations of existing evidence. Papers that add statistical mass to what the clinical field already knows, or that confirm an established intervention remains effective in a new cohort, face consistent desk rejection regardless of study size or methodological rigor.

Methodological or reporting gaps visible at the desk. The Lancet's editorial review process includes early methodology assessment. We see this failure regularly in manuscripts we review: missing CONSORT flow diagrams for trials, absent PRISMA documentation for systematic reviews, or observational analyses with unaddressed confounding. These gaps generate desk returns before the paper reaches statistical review.

SciRev community data for The Lancet confirms desk decisions typically within 1-2 weeks and post-review first decisions within 2-4 weeks, reflecting the fast editorial process The Lancet maintains as one of the world's highest-volume flagship medical journals.